Waltham, MA, United States
Waltham, MA, United States
SEARCH FILTERS
Time filter
Source Type

News Article | June 22, 2017
Site: globenewswire.com

BETHLEHEM, Pa., June 22, 2017 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced the appointment of Ms. Mara G. Aspinall as a member of the Company's Board of Directors.  Ms. Aspinall will serve as a Class II Director with an initial term expiring at the Company’s 2020 Annual Meeting of Stockholders.  She will also serve on the Audit and Compensation Committees of the Board. "We are pleased to welcome Mara as a new member of the Company’s Board of Directors," said Stephen S. Tang, Ph.D., Chairman of the OraSure Technologies Board of Directors.  "Mara’s executive leadership and extensive background in life sciences, especially in the molecular and diagnostics fields, make her an ideal addition to our Board.  This is an exciting time for OraSure and I am confident that Mara will be a valuable contributor as the Company continues to grow and execute against its strategic priorities." Ms. Aspinall currently serves as the President and CEO of Health Catalysts, an investment and advisory firm that focuses on growth of early stage life science and technology companies.  She also currently serves as the Executive Chairman of GenePeeks, a computational genomics company offering proprietary technology to help identify the pre-conception risk of passing on monogenic disease to progeny. Prior to these positions, Ms. Aspinall served as President and CEO, Global Head of Roche Tissue Diagnostics, where she led Ventana Medical Systems, a division of the Roche Group that provides tissue-based cancer diagnostic instruments, products and services.  Prior to that she founded and served as CEO and Director of On-Q-ity, Inc., a diagnostic research company focused on improving cancer treatment through the capture of circulating tumor cells in a patient’s blood.  Ms. Aspinall also spent 12 years with Genzyme Corporation, serving as President of the Genzyme Genetics division, a leading provider of esoteric and genetic tests for the reproductive, oncology and personalized medicine markets, and as President of the Genzyme Pharmaceuticals division, a custom pharmaceutical intermediates provider.  Ms. Aspinall began her career as a management consultant with Bain & Company. Ms. Aspinall co-founded the International School of Biomedical Diagnostics at Arizona State University, the first school dedicated to diagnostics as an independent discipline.  In addition, she has taught in the area of diagnostics at the University of Arizona School of Medicine, Harvard Medical School and Boston University School of Management, and is a frequent national speaker on healthcare related issues. Ms. Aspinall is a member of the Harvard Business School Healthcare Initiative Advisory Board, was recognized as Arizona BioSciences (“AZBio”) Leader of the Year in 2016 and has authored a number of articles for health-care industry publications.  In addition to her Board service at GenePeeks, Ms. Aspinall currently serves on the Boards of Abcam Plc (AIM:ABC) and Allscripts (NASDAQ:MDRX), and has served on various councils and boards of organizations within her community for the past decade. Ms. Aspinall holds an M.B.A. from Harvard Business School and a B.A. in International Relations from Tufts University. OraSure Technologies is a leader in the development, manufacture and distribution of point of care diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. Its first-to-market, innovative products include rapid tests for the detection of antibodies to HIV and HCV on the OraQuick® platform, oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications, and oral fluid laboratory tests for detecting various drugs of abuse. OraSure's portfolio of products is sold globally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, research and academic institutions, distributors, government agencies, physicians' offices, commercial and industrial entities and consumers. The Company's products enable healthcare providers to deliver critical information to patients, empowering them to make decisions to improve and protect their health. For more information on OraSure Technologies, please visit .


The invention features devices and methods for detecting, enriching, and analyzing circulating tumor cells and other particles. The invention further features methods of diagnosing a condition, e.g., cancer, in a subject by analyzing a cellular sample from the subject.


This present invention compositions and methods of treating, diagnosing, prognosing cancer and methods of accessing/monitoring the responsiveness of a cancer cell to a therapeutic compound.


Method of enriching specific cells from cellular samples are disclosed, comprising contacting in solution a cellular sample with affinity-tagged ligands (ATLs) each comprising a first ligand linked to an affinity tag, wherein the ligand selectively binds a cellular marker of the rare cells and the affinity tag can be selectively captured by a capture moiety, wherein the affinity tags do not comprise a magnetic particle; and flowing the sample through a microfluidic device comprising the capture moiety to selectively retain ATL-bound cells. Methods for enriching circulating tumor cells, and devices for enriching specific cells from cellular samples are also disclosed.


The present invention provides materials and methods for predicting the response of a disease state to a therapeutic agent. A targeting moiety specific for a biological marker is labeled with a reporter moiety and used to analyze cells characteristic of the disease state. The output of the reporter moiety, which may be fluorescence intensity, is compared to the output of reference standard analyzed under similar or identical conditions. The use of a reference standard allows biomarker reporting to be normalized. Biomarker values can then be correlated from sample to sample and from laboratory to laboratory based on quantitative calibration on a universal reference standard.


Method of enriching specific cells from cellular samples are disclosed, comprising contacting in solution a cellular sample with affinity-tagged ligands (ATLs) each comprising a first ligand linked to an affinity tag, wherein the ligand selectively binds a cellular marker of the rare cells and the affinity tag can be selectively captured by a capture moiety, wherein the affinity tags do not comprise a magnetic particle; and flowing the sample through a microfluidic device comprising the capture moiety to selectively retain ATL-bound cells. Methods for enriching circulating tumor cells, and devices for enriching specific cells from cellular samples are also disclosed.


News Article | February 15, 2012
Site: www.xconomy.com

Informed decisions will improve the way cancer is treated. On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Our platform will enable better decision-making across multiple cancers: improving the quality of life for patients and ultimately increasing survival.


News Article | March 19, 2015
Site: www.businesswire.com

NEW YORK & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Lifeprint Group, the parent company for GenePeeks, Inc., a genetic information company focused on next-generation disease risk analysis, announced today that Mara Aspinall has joined the company’s Board of Directors as Executive Chairman. Aspinall brings deep experience building and leading successful life science companies to support the company’s continued growth. “We are privileged to welcome Mara as the new Chairman of our Board of Directors,” said Anne Morriss, CEO of GenePeeks. “Her leadership at the intersection of genomics, diagnostics and personalized medicine is incredibly valuable to us as we continue to develop our patented platform and work towards helping any family who wants to protect their future children from serious genetic diseases.” GenePeeks digitally combines the DNA information of prospective parents to create “Virtual Progeny” and evaluate their risk for more than 500 recessive genetic diseases. The company’s innovative approach uses a next-generation sequencing platform to look deep inside a future child’s potential genome to uncover disease risk that cannot be seen with existing pre-pregnancy screening tools. “GenePeeks is bringing computational genomics to the challenge of reducing risk for life-threatening and life-altering diseases,” said Aspinall. “I look forward to sharing my insight and experience with the GenePeeks leadership team to help make the company’s breakthrough analysis available to as many parents as possible. In a world where all of us carry hidden risk inside our genes, there is enormous power in seeing this risk in advance of a pregnancy and capturing the true complexity of reproductive genetics.“ Aspinall is the former President and CEO of Ventana Medical Systems. Ventana, a member of the Roche Group, is a worldwide leader in the development, manufacture and commercialization of tissue-based cancer diagnostics that enable the delivery of personalized healthcare to patients. During her tenure, Ventana substantially grew its financial and market position, establishing the company as a leading oncology companion diagnostics firm. She currently serves as the CEO of Health Catalysts, a consulting firm dedicated to increasing the growth and impact of early stage life sciences companies. Previously, Aspinall spent 12 years with Genzyme Corporation where she held leadership roles that included President of Genzyme Genetics and President of Genzyme Pharmaceuticals. She was the Founder, CEO and Director of On-Q-ity, a diagnostic research company focused on transforming cancer patient treatment and treatment outcomes through the capture of circulating tumor cells (CTCs) in a patient’s blood. Aspinall is a Director of Safeguard Scientific (NYSE:SFE), a company providing growth capital for entrepreneurial and innovative healthcare and technology companies, as well as Castle Biosciences. She served for more than a decade on the Board of the Dana Farber Cancer Institute, chairing the Science Committee and as a Board member of Blue Cross Blue Shield Massachusetts. In addition, Aspinall was an active member of the Secretary of Health and Human Services’ Advisory Council on Genetics in both the Obama and Bush administrations. GenePeeks is a genetic information company focused on identifying inherited disease risk in future generations. GenePeeks’ proprietary technology digitally combines the genetic information of two potential parents, simulating the complex genetic interactions that occur naturally in human reproduction. The company’s patented platform creates and analyzes thousands of Virtual Progeny to uncover disease risk that cannot be seen with existing pre-pregnancy screening tools. GenePeeks was founded by CEO Anne Morriss and Lee Silver, Professor of Molecular Biology at Princeton University, to help families protect their future children from serious diseases. GenePeeks is privately held by Lifeprint Group, with offices in New York, NY and Cambridge, MA. For more information, visit www.genepeeks.com.


News Article | March 19, 2015
Site: www.businesswire.com

NEW YORK & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Lifeprint Group, the parent company for GenePeeks, Inc., a genetic information company focused on next-generation disease risk analysis, announced today that Mara Aspinall has joined the company’s Board of Directors as Executive Chairman. Aspinall brings deep experience building and leading successful life science companies to support the company’s continued growth. “We are privileged to welcome Mara as the new Chairman of our Board of Directors,” said Anne Morriss, CEO of GenePeeks. “Her leadership at the intersection of genomics, diagnostics and personalized medicine is incredibly valuable to us as we continue to develop our patented platform and work towards helping any family who wants to protect their future children from serious genetic diseases.” GenePeeks digitally combines the DNA information of prospective parents to create “Virtual Progeny” and evaluate their risk for more than 500 recessive genetic diseases. The company’s innovative approach uses a next-generation sequencing platform to look deep inside a future child’s potential genome to uncover disease risk that cannot be seen with existing pre-pregnancy screening tools. “GenePeeks is bringing computational genomics to the challenge of reducing risk for life-threatening and life-altering diseases,” said Aspinall. “I look forward to sharing my insight and experience with the GenePeeks leadership team to help make the company’s breakthrough analysis available to as many parents as possible. In a world where all of us carry hidden risk inside our genes, there is enormous power in seeing this risk in advance of a pregnancy and capturing the true complexity of reproductive genetics.“ Aspinall is the former President and CEO of Ventana Medical Systems. Ventana, a member of the Roche Group, is a worldwide leader in the development, manufacture and commercialization of tissue-based cancer diagnostics that enable the delivery of personalized healthcare to patients. During her tenure, Ventana substantially grew its financial and market position, establishing the company as a leading oncology companion diagnostics firm. She currently serves as the CEO of Health Catalysts, a consulting firm dedicated to increasing the growth and impact of early stage life sciences companies. Previously, Aspinall spent 12 years with Genzyme Corporation where she held leadership roles that included President of Genzyme Genetics and President of Genzyme Pharmaceuticals. She was the Founder, CEO and Director of On-Q-ity, a diagnostic research company focused on transforming cancer patient treatment and treatment outcomes through the capture of circulating tumor cells (CTCs) in a patient’s blood. Aspinall is a Director of Safeguard Scientific (NYSE:SFE), a company providing growth capital for entrepreneurial and innovative healthcare and technology companies, as well as Castle Biosciences. She served for more than a decade on the Board of the Dana Farber Cancer Institute, chairing the Science Committee and as a Board member of Blue Cross Blue Shield Massachusetts. In addition, Aspinall was an active member of the Secretary of Health and Human Services’ Advisory Council on Genetics in both the Obama and Bush administrations. GenePeeks is a genetic information company focused on identifying inherited disease risk in future generations. GenePeeks’ proprietary technology digitally combines the genetic information of two potential parents, simulating the complex genetic interactions that occur naturally in human reproduction. The company’s patented platform creates and analyzes thousands of Virtual Progeny to uncover disease risk that cannot be seen with existing pre-pregnancy screening tools. GenePeeks was founded by CEO Anne Morriss and Lee Silver, Professor of Molecular Biology at Princeton University, to help families protect their future children from serious diseases. GenePeeks is privately held by Lifeprint Group, with offices in New York, NY and Cambridge, MA. For more information, visit www.genepeeks.com.

Loading On-Q-ity collaborators
Loading On-Q-ity collaborators